Author: Anastasia Madenidou
Wittoek et al. (OP0071) explored the benefits of denosumab in patients with erosive hand OA. One hundred patients with erosive hand OA were randomly allocated to placebo or denosumab 60mg every three weeks in a monocentric clinical trial during 48 weeks, followed by an open-label extension phase through week 96. The primary endpoint was change in total Ghent University Scoring System (GUSS) score at week 24. GUSS is a semi-quantitative scoring system specifically developed to combine scoring of both erosive progression and signs of repair, and able to detect changes in the short term. Total change GUSS was found statistically higher in denosumab compared to placebo at week 24 (mean change GUSS = 8.9 (95% CI: 1.0 to 16.9). Development of new erosive joints was significantly lower in denosumab (1.8%) compared to placebo (p < 0.001), suggesting that denosumab has clear structure modifying effects in erosive hand OA.
Heijman et al. (OP0072) examined whether colchicine 0.5mg daily reduces the incidence of knee and hip replacements by performing a post-hoc analysis of data collected in the LoDoCo2 trial. The use of colchicine 0.5 mg daily was associated with a reduced risk of knee and hip replacements (hazard ratio 0.69 (95% CI: 0.51-0.95)).
Yazici et al. (POS1351) assessed the safety and tolerability of repeated 6-month knee injections of lorecivivint in a 104-week trial (NCT03727022). Lorecivivint is a CLK/DYRK inhibitor thought to modulate Wnt and inflammatory pathways and is in development as a potential knee OA treatment. The study showed that the incidence of AEs was similar between lorecivivint and placebo.
Palmowski et al. (OP0243) assessed the effect of regular PPI intake on bone mineral density (BMD) and microarchitecture in patients with inflammatory rheumatic and musculoskeletal diseases. 1,495 patients from the single-centre Rh-GIOP cohort (“Glucocorticoid-induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases or Psoriasis”) were included. In an adjusted model, PPI users had lower BMD at both the left femoral neck (-0.17, 95% CI: -0.35 to 0.01) and the lumbar spine (-0.25, 95% CI: -0.47 to -0.04) compared to non-users.
Mok et al. (OP0246) compared the efficacy and safety of romozosumab and denosumab in high-risk patients with glucocorticoid (GC)-induced osteoporosis in a pilot open randomised controlled trial (n=70). Romosozumab was superior to denosumab in raising the spine BMD at month 12 in chronic GC users with high fracture risk (p<0.001).
Through performing a Delphi exercise, Jackson et al. (POS0393) developed a numeric additive decision rule to classify clinicians across multiple specialties with competence in evaluating and treating patients with osteoporosis.
ABOUT THE AUTHOR
Anastasia Madenidou
Anastasia is a Rheumatology trainee and a Clinical Research Fellow at the Centre of Musculoskeletal Research, University of Manchester.
Her research work focuses on precision medicine strategies in lupus spectrum disorders.
Anastasia is the Deputy Chair of the British Rheumatology Society Trainee Committee and a member of the Newsletter Sub-Committee.